Abstract. Targeting drugs to receptors involved in tumor angiogenesis is considered to be a novel and promising approach to improve cancer treatment. . The biodistribution study of 188 Re-rhk5 showed that 188 Re-rhk5 had a high initial tumor uptake and prolonged tumor retention. The highest tumor uptake of 188 Re-rhk5 (3.65±0.82% ID/g) was found 2 h after injection which decreased to 0.81±0.14% ID/g 12 h after injection. Following therapy, tumor size measurement indicated that 188 Re-rhk5-treated tumors were smaller than 188 Re-, rhk5-and saline-treated controls 6 days after the treatment. In vivo 18 F-FDG micro-PET imaging showed significantly reduced tumor metabolism in the 188 Re-rhk5-treated mice vs. those treated with rhk5, 188 Re and saline control, 1 day after treatment. Moreover, the number of microvessels was significantly reduced after 188 Re-rhk5 treatment as determined by CD31 staining. Our results demonstrate that specific delivery of 188 Re-rhk5 allows preferential cytotoxicity to A549 lung cancer cells and tumor vasculature.
Introduction
Angiogenesis plays an important role in the process of tumor proliferation and migration. Intervention in any one of these processes affects angiogenesis and, consequently, inhibits tumor growth (1). Kringle 5 (k5), an internal proteolytic fragment of plasminogen, is an inhibitor of angiogenesis. It has a low molecular weight protein (14 kDa), with low immunocompetence, which has the most potent anti-angiogenic effect compared to other kringle fragments of plasminogen, including widely used angiostatin (2) . However, a high dosage of inhibitor is required for tumor treatment, and these doses are not cost-effective for clinical application. By combining well-selected radionuclides with disease-specific drugs, the administration of radiolabeled drugs provides a functional imaging and efficient internal radiotherapy mode for localized as well as metastatic lesions (3, 4) . Although
131
I is a widespread radioisotope used for tumor imaging and therapy, the use of 188 Re from the 188 W/ 188 Regenerator system is an attractive alternative radionuclide. 188 Re has a physical half-life of 16.9 h and, in addition to the emission of high-energy electrons (E β =2.118 MeV), 188 Re also decays with emission of a γ-photon with an energy of 155 keV. Apart from the therapeutic usefulness of 188 Re, the biodistribution of 188 Re-labeled proteins can be evaluated in vivo. Since lung cancer is the most common cause of cancer-related mortality, the role of angiogenesis is well established in the progression of lung cancer (5) . Consequently, 188 Re-labeled recombinant human plasminogen kringle 5 ( 188 Re-rhk5) radiotherapy was assessed in the experimental mouse models of lung cancer.
Methods that reliably evaluate and predict anti-tumor effects following therapy are currently rare. The ability to predict which type of therapy is effective at the early stage of treatment would be invaluable for drug selection. Conventional anatomic imaging modalities, such as computed tomography and endoscopic ultrasonography, reveal the cancer response as changes in tumor size and composition, which may occur only after weeks or months after therapy, and are not ideally suitable for the early prediction of tumor response (6). Positron emission tomography (PET) with the glucose analogue [ 18 F]-fluorodeoxyglucose (FDG) is a method utilized to monitor treatment responses (7). Thus, we evaluated the antitumor efficacy of 188 Re-rhk5 using 18 F-FDG micro-PET.
Materials and methods

General.
Rhk5 was expressed as previously described with some modifications (8 + was prepared by a previously described method (9, 10) , with some modifications. Radiolabeling of rhk5 was performed by a previously described method with some modifications (11) . Briefly, powdered BH 3 -NH 3 (5 mg) was placed into a 10-ml glass vial. The vial was sealed and flushed with CO for 20 min, and a mixture of 6 µl phosphoric acid (85%) and 1 ml of perrhenate (740-1110 MBq) was added to the vial. The vial was then heated in a water bath at 75˚C for 15 min Tissue biodistribution of 188 Re-rhk5. A total of 25 A549 tumor-bearing Balb/C nude mice were anesthetized by an i.p. injection of pentobarbital sodium (150 mg/kg). The mice were randomly divided into 5 groups (n=5 per group). Each animal received a 0.74 MBq intravenous (i.v.) injection of 188 Re-rhk5 to evaluate the biodistribution of the tracer in the major organs. Five of the mice were sacrificed at 0.5, 1, 2, 4 and 12 h after injection of 188 Re-rhk5, respectively. The principal organs, as well as blood and muscle samples, were removed and collected, washed with saline, weighed and counted using the gamma-counter. Tissue counts were corrected for background and decay during the time of counting. The results were presented as the percentage of the injected dose per gram of net weight (% ID/g). Each value is the mean ± SD of 5 animals.
In order to verify the binding specificity of 188 Re-rhk5, a blocking experiment was performed. In the blocking group, 5 tumor-bearing nude mice were used and each animal was administered 0.74 MBq 188 Re-rhk5 along with 100 µg rhk5. The animals were then presented for the biodistribution study 2 h post-injection, using the same procedure as above. The biodistribution data between the two groups were compared.
Treatment of A549 lung cancer model. A total of 24 mice were used. When palpable tumors were present in all animals (200-300 mm 3 ), the mice were randomly divided into 4 groups (n=6 per group). Group 1 was treated with 188 Re-rhk5 (37 MBq). As controls, Groups 2, 3 and 4 were treated with 188 Re (37 MBq), rhk5 (5 µg) and 0.9% saline, respectively. Considering the therapeutic efficacy and renal toxicity, the agents were injected directly into the tumor site. The tumor volume was measured every 3 days up to 18 days before euthanasia. 
Micro-PET/CT imaging.
In the model, progression of the A549 xenografted tumors was determined by imaging mice treated with 188 Re-rhk5 at different time points (prior to 188 Re-rhk5 treatment and after 1, 6 and 18 days). Mice were sacrificed following completion of the last imaging, and histological assessment was performed to correlate tumor progression with micro-PET results.
After 8 h of fasting, CT images were initially obtained. The X-ray voltage was set at 80 kV, with a current of 500 µA. The total CT scan time was 10 min. The PET data were obtained at the same anatomic locations. Mice were injected with ~7. 4 MBq of 18 F-FDG via tail vein under isoflurane anesthesia. The mice received 5% isoflurane in oxygen during rapid inhalation induction anesthesia (1-2 min). Maintenance of anesthesia during each scan was achieved using 1.5% isoflurane in oxygen. PET scans (20-min) were performed at 1 h post-injection (p.i.). The images were reconstructed by a three-dimensional ordered subset expectation maximum algorithm. All corrections for attenuation, scatter, dead time and randoms were applied to generate quantifiable images. The plane in which the tumor appeared largest on the CT image was selected. An irregular region of interest covering the whole tumor on CT was drawn and then copied to PET in the same mirror image. The maximum standardized uptake values (SUVmax) were determined.
Histopathological and immunohistochemical analysis. The mice were sacrificed using an overdose of pentobarbitone. Tumors were harvested in 4% buffered formaldehyde for 24 h, processed in paraffin, sectioned at 3 µm and stained with hematoxylin and eosin for histopathological examination.
For immunoreactivity staining, 5-µm deparaffinized polysincoated sections were treated with 3% hydrogen peroxide for non-specific binding. A CD31 antibody (with a dilution of 1:200) was employed for immunohistochemical staining using the peroxidase-antiperoxidase technique.
Statistical analysis. Statistical significance was determined by one-way ANOVA using the Computer Statistical Package for the Social Sciences (SPSS 16.0). P<0.05 was considered to be statistically significant. 188 Re-rhk5 was 60-75% after purification, and RCP was >96%. Therefore, 188 Re-rhk5 was adequately prepared, with a concentration of 280-390 MBq/ml, and was ready for the experiments.
Results
Labeling
Biodistribution study. Fig. 1A shows the biodistribution data at 0.5, 1, 2, 4 and 12 h post-injection. The radiotracer exhibited a rapid decrease in radioactivity over time in blood and the majority of organs. At early time points, the high kidney activity was evidently attributable to the elimination of 188 Rerhk5 in the urine. The highest tumor uptake of 188 Re-rhk5 (3.65±0.82% ID/g) was found 2 h after injection and decreased to 0.81±0.14% ID/g 12 h after injection, suggesting that the 188 Re-rhk5 was present in the tumor up to at least 12 h after injection.
When blocked by a co-injection of rhk5 at a dose of 100 µg per mouse, the tumor uptake decreased from 3.65±0.82 to 1.44±0.28% ID/g for the A549 tumors 2 h after injection. Blocking reduced the tumor uptake of the tracer, clearly indicating specific binding. In contrast, co-injection of a large excess of rhk5 resulted in no change in the uptake of 188 Re-rhk5 in the remaining organs (Fig. 1B) . The findings suggest that the tumor uptake of 188 Re-rhk5 occurs via a receptormediated process. 188 Re-rhk5 treatment. To determine whether 188 Re-rhk5 has an anti-tumor effect in vivo as we proposed, female athymic nude mice-bearing A549 tumors were randomly divided into 4 groups and i.v. injected once with 188 Re-rhk5 (37 MBq), 188 Re (37 MBq), rhk5 (5 µg) and 0.9% saline. Prior to therapy, no significant difference was found in the tumor volume among the 4 groups (Fig. 2) . The tumor volume in the 4 groups increased gradually on day 3, but no significant differences were noted among the groups at these time points (P>0.05). 188 Re-rhk5-treated tumors started to show growth retardation as compared to the 0.9% saline-treated group (P<0.05) at day 6 after initiation of treatment. The 188 Re group also showed a decrease in tumor growth compared to the 0.9% saline-treated group (P<0.05). However, no difference was found between the 188 Re-and 188 Re-rhk5-treated groups on day 6 . It was found that 18 days after therapy the tumor volume was significantly smaller in the 188 Re-rhk5-treated group than in the controls (P<0.01).
Changes in tumor volume following
F-FDG micro-PET imaging.
18 F-FDG micro-PET is a functional imaging technique that expresses the glycolytic rate of tissues and has been used to measure the increased metabolic The accumulation of 18 F-FDG in tumor lesions prior to therapy was evident (Fig. 3) . On day 1, a decrease in the 18 F-FDG uptake was evident in the 188 Re-rhk5 group. Uptake was also decreased in the 188 Re group, but not in the 2 control groups, which showed signs of increase. Changes in tumor size were a late sign; only at day 6 was there a distinction among the groups (Fig. 2) . Due to the rapid proliferation and invasiveness of the malignant tumors, a single dose of 188 Re-rhk5 did not eliminate all viable tumor cells. The remaining tumor cells proliferated rapidly; 18 F-FDG uptake increased following a rapid decrease after 188 Re-rhk5 treatment. On day 18, 18 F-FDG uptake of all the control groups was increased, while the uptake of the 188 Re-rhk5-treated group remained less than that of the control groups.
The tumor uptake of 18 F-FDG (SUVmax) was decreased from 0.72±0.18 to 0.31±0.08% ID/g in the 188 Re-rhk5-treated group (P<0.01), and from 0.74±0.10 to 0.50±0.08% ID/g in the 188 Re-treated group (P<0.01) (Fig. 4) . Both rhk5-and saline-treated groups exhibited no change in SUVmax. After day 6, both 188 Re-rhk5-and 188 Re-treated groups showed a low level of SUVmax similar to that on day 1. However, the remaining two groups showed an increased SUVmax. The SUVmax of the 188 Re-rhk5-treated group was lower than that at pre-therapy, even 18 days after therapy. However, the remaining 3 groups reached a higher level of SUVmax than that at pre-treatment.
Histological analysis.
To further confirm the effectiveness of the use of 188 Re-rhk5 treatment, we performed a histological analysis on the dissected tumors (Fig. 5) . Mice treated with 188 Re-rhk5 showed a marked necrosis compared to the other 3 groups. CD31 staining was carried out to study the effect of 188 Re-rhk5 treatment on vascular damage. It was found that CD31 expression was decreased in the 188 Re-rhk5 group when compared to the 188 Re, rhk5 and saline groups. Therefore, by combining the use of bioimaging techniques as well as histo- Re-rhk5 (37 MBq), 188 Re (37 MBq), rhk5 (5 µg) and 0.9% saline at various time points (0, 3, 6 and 18 days) is shown. 18 F-FDG micro-PET was performed 1 h after injection with 200 µCi 18 F-FDG. Implanted tumors are located on the right hind limbs of mice. SUVmax was calculated. logical analysis, we demonstrated that 188 Re-rhk5 therapy is effective against A549 xenografts in a mouse model.
Discussion
The development of successful tumor imaging and radiopharmaceutical therapy requires a detailed understanding of the target molecules. Consequently, the targets for rhk5 on endothelial cells have been studied. It is known that rhk5 specifically binds to endothelial cell surface ATP synthase (12) . The present biodistribution and blocking study confirmed the specificity of rhk5 binding.
Radioimmunotherapy of tumors using molecules labeled with β-emitters has been proposed as part of a combined modality approach in order to improve the prognosis of patients (13, 14) . Positive clinical responses have been achieved by a number of investigators (15, 16) . The systemic administration of radiopharmaceuticals for therapeutic purposes is limited by various factors, such as high interstitial pressure inside the neoplastic tissue, limited blood supply to the tumor, inhomogeneous and inconsistent antigen expression, possible presence of histopathological barriers (necrosis or fibrosis) and catabolism of immunoglobulins (17) . These factors result in a very low accumulation of the radiopharmaceutical in the target tissue, which in most cases prevents a favorable therapeutic effect.
In the present study, by targeting neovessels, the tumor specificity of rhk5 and cytotoxic effect of 188 Re were observed. We evaluated the tumor therapeutic effect of 188 Re-rhk5 in vivo, with 188 Re, rhk5 and saline-only treatment serving as controls. In subsequent experiments, the tumor response to therapy was confirmed by tumor volume measurement, 18 F-FDG PET and in vitro histopathological validation.
Following the measurement of tumor size, mice treated with 188 Re-rhk5 exhibited a slower tumor growth than 188 Re-, rhk5-and saline-treated controls. 188 Re treatment also exhibited a delay in tumor growth when compared to the rhk5 treatment group and saline controls. 18 F-FDG PET revealed a reduced tumor metabolism following 188 Re-rhk5 and 188 Re treatment, which concurred with the observation that 188 Re-rhk5 and 188 Re decreased the rate of tumor growth; although the tumor volume still increased with time despite the 188 Re-rhk5 administrations. This study showed that 18 F-FDG PET was suitable for depicting early glycolytic rate reductions in A549 tumors (1 day after therapy) in pre-clinical models following 188 Re-rhk5 therapy before changes in tumor size were evident. Further studies are required to determine whether 18 F-FDG PET distinguishes between varying degrees of treatment response, predicts a pathologic complete response, and detects early biological changes during the regrowth phase following ineffective therapy. Results of in vitro immunohistochemistry revealed that 188 Re-rhk5 is more effective than 188 Re or rhk5 in terms of eradicating tumor vasculature. Further studies to evaluate the effect of various doses and treatment frequencies are required to optimize treatment efficacy.
Our study is novel in that it compared the diagnostic values of micro-PET/CT and conventional histological or morphological analysis. Although histological analysis is extremely useful and accurate for diagnosing and staging diseases, such as lung tumors, its procedures are time-consuming and require expertise to interpret the results. This is true in clinical practice. Despite being the most definite assessment of lung cancer grading, histological examination using percutaneous needle biopsy is invasive and the specimen retrieved does not always represent the entire lesion due to sampling errors (18) . On the other hand, the use of bioimaging modalities overcomes these obstacles. Compared to conventional single bioimaging modality, such as CT, MRI or ultrasonography, 18 F-FDG PET has advantages in the evaluation of malignancies, including diagnosing, staging tumors, evaluating biological characteristics and monitoring tumor progression. Similarly, our results derived from micro-PET corresponded with that of a standard histological analysis. Such findings have great impact on future experimental design, since the use of bioimaging modalities, such as micro-PET, means that histological analysis will not be required at each stage, allowing for serial follow-up and assessment in the last stages of the disease.
Despite the successful demonstration of 188 Re-rhk5 delivery to A549 tumor therapy, there are several limitations to the present study. Although 188 Re-rhk5 showed a higher tumor uptake and longer retention in A549 tumors, the 188 Rerhk5, 188 Re, rhk5 and 0.9% saline on A549 xenografts. All of the tests were performed 18 days after treatment. Representative histological sections (A-D) and CD31 immunohistochemical analysis (E-H) for A549 xenografts (magnification, x40).
absolute tumor uptake value was relatively low, due in part to the hydrophilic character of rhk5 and the small molecular size, leading to a short circulation half-life and rapid kidney clearance. Widespread necrosis was also found in the control groups. This also confirms our previous hypothesis that the lower SUVmax readings exhibited by the control group compared to mice treated only with 188 Re-rhk5 were due to a large volume of necrotic cells. Our tumor model was an animal model and the time course of 18 F-FDG uptake may be different in humans. In addition, the behavior of 18 F-FDG uptake in A549 tumors may not be representative of that in other types of tumors.
Our results indicate that the specific inhibition of A549 tumor growth with 188 Re-rhk5 provides an effective novel treatment modality for lung cancer. 18 F-FDG PET is a non-invasive imaging tool with which to assess early tumor responses to 188 Re-rhk5 therapy. Further improvement of the treatment efficacy is currently in progress.
